COMP <GO>
STIM vs MRK // GROSS PROFIT MARGIN
Neuronetics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: STIM 1
— MRK 10
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $2.38 (+5.31%) • MKT CAP: $181.3M
gross-margins
48.50%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STIM VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STIM | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 48.50% | 74.80% | -26.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -11.25% | 3.42% | -14.67 | MRK | /fcf-yield <GO> |
| Operating Margin | -21.10% | 34.30% | -55.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -26.10% | 28.10% | -54.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 99.20% | 1.30% | +97.90 | STIM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 51.7 | -1.64 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $181.3M | $361.02B | -$360.84B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STIM REV | MRK REV | STIM GROSS % | MRK GROSS % | STIM FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $149.2M | $65.01B | 48.5% | 74.8% | -$20.4M | $12.36B |
| FY 2024 | $74.9M | $64.17B | 72.3% | 76.3% | -$31.0M | $18.10B |
| FY 2023 | $71.3M | $60.12B | — | — | -$32.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STIM // BETA —
MRK // BETA 0.92